According to a recent LinkedIn post from FluoretiQ Limited, research in the Journal of the American Veterinary Medical Association is cited indicating that 29% of animals in a sample of 2,599 dogs and cats received antibiotics, while only 13% underwent diagnostic testing beforehand. The post frames this gap as a timing issue between rapid prescribing decisions in 15‑minute consultations and culture results that can take 24 to 72 hours.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The LinkedIn post highlights that when cost barriers to diagnostics were removed and a decision support tool was introduced, empirical prescribing reportedly decreased and treatment durations shortened. FluoretiQ positions its Veri-5 Vet product as a point‑of‑care test that can identify common urinary pathogens in about 15 minutes, bringing diagnostic data into the consultation window.
For investors, this messaging suggests FluoretiQ is targeting a defined stewardship problem in veterinary practice that is supported by published data across 52 U.S. veterinary practices. If adoption of rapid diagnostics such as Veri-5 Vet scales, it could create a recurring revenue opportunity tied to antimicrobial stewardship and practice efficiency trends.
The post also aligns the company with broader themes of antibiotic stewardship and antimicrobial resistance, areas that attract regulatory and professional attention. This positioning may help FluoretiQ differentiate within the veterinary diagnostics market and potentially support future partnerships with clinics, reference labs, or larger animal health players.